Objective: Infliximab is a chimeric antibody which binds tumor necrosis factor (TNF). It is
effective in several chronic inflammatory conditions, including sarcoidosis. Methods: We …

Objective Infliximab, a monoclonal antibody against tumor necrosis factor α, is approved by
the US Food and Drug Administration for treatment of numerous autoimmune disorders. We …

Objective To report the outcomes of infliximab therapy in the treatment of ocular
inflammatory disease refractory to traditional immunomodulatory therapy (IMT). Methods We …

OBJECTIVE: To assess the efficacy and safety of the anti–tumor necrosis factor α agent
infliximab in treatment-resistant uveitis and scleritis. DESIGN: Retrospective …

Infliximab is a chimeric human-murine monoclonal antibody of the IgG1 type with a high
affinity and specificity for tumor necrosis factor alpha (TNFalpha). Infliximab was used in …

Aims: Experience with anti-tumour necrosis factor α medications in ophthalmology has been
mainly in the treatment of resistant uveitis and scleritis. There have been a few case reports …

Introduction Adalimumab, a humanized monoclonal antibody targeted against TNF-α, has
proved to be successful in the treatment of uveitis. Another anti-TNF-α agent, ie, infliximab …

PURPOSE: Anti–tumor necrosis factor α (anti–TNF-α) agents are being used increasingly in
refractory inflammatory eye diseases. We reviewed our patients on etanercept and infliximab …

Objective To establish the safety and efficacy of infliximab for the treatment of refractory
noninfectious uveitis. Design Retrospective, interventional, noncomparative cohort study …

Purpose: To describe the corticosteroid-sparing success in controlling chronic uveitis in
patients treated with TNFα inhibitors. Methods: Retrospective longitudinal case series of …